STOCK WATCH

AN announcement from SkinBioTherapeutics yesterday that it had achieved a ‘significant’ manufacturing scale-up did not impress shareholders enough to keep share price in the black.

The company has created a technology called Skinbiotix, derived from probiotic bacteria, which aims to protect skin from infection and repair it.

It added that the material has now been freeze-dried, enabling mass production and transport. Shares slipped 17.3pc, or 4.15p, to 19.85p.